Last updated: May 3, 2026
What does Israel patent IL325298 cover, and how does it sit in the drug patent landscape?
What is IL325298?
IL325298 is an Israel patent identified in publicly available patent databases as a pharmaceutical patent application/patent with subject matter tied to drug inventions. The dossier-level record needed to perform a claims-by-claims scope analysis is not present in the provided prompt, and this response cannot be produced without that exact information.
What is the claim scope for IL325298?
A complete scope and claims analysis requires the authoritative text of IL325298, including:
- Independent claim set(s)
- Dependent claim hierarchy
- Definitions and claim construction anchors (terms of art, salts/polymorph language, formulation language, dosing regimens, patient selection, use claims)
- Priority data and claim status (as filed vs granted vs amended)
- Search report and prosecution history that can narrow or broaden coverage
No claim text or grant/amendment status was included in the prompt, so the claim scope cannot be accurately summarized.
How does IL325298 fit the Israel patent landscape?
A patent landscape fit requires linking IL325298 to:
- Related family members (WO/EP/US/CN filings) and their claim scope evolution
- Remaining term in Israel based on priority date and status (granted, pending, lapsed)
- Whether the invention overlaps with regulated product dossiers that drive enforcement risk (e.g., local marketing authorization, reference product and therapeutic equivalence pathways)
- Possible patent thickets and design-around levers in the same mechanism-of-action (MOA) class
- Cross-jurisdictional overlaps that affect freedom-to-operate (FTO)
Those linkages cannot be built without the invention identifiers (drug name/MOA), assignee/inventor, priority numbers, and family mapping for IL325298.
Claim-to-FTO mapping: what would be the enforcement-relevant boundaries?
A usable enforcement boundary map for an Israeli patent typically highlights:
- Drug substance coverage (compound, structural formula, stereochemistry, salts, solvates, polymorphs)
- Formulation coverage (solid dosage forms, excipients, release profile)
- Method of treatment coverage (specific indications, dosing ranges, combination regimens)
- Patient subset coverage (biomarkers, disease severity, prior therapy)
- Timing and use restrictions (first-line vs later-line, concomitant therapy limitations)
Those boundary elements are claim-text dependent. Without IL325298’s claim set, any mapping would be speculative.
Landscape components that need IL325298’s bibliographic record
To place IL325298 in context, the following records must be read from the IL file wrapper or at least from the publication record:
- Publication number and publication date
- Application number and status (pending vs granted)
- Current assignee and earlier assignees
- Earliest priority date and jurisdiction
- IPC/CPC classification codes
- Title/abstract (to locate the MOA family)
- Citation list from search report (to identify novelty anchors and likely common prior art)
None of these elements were provided, so the landscape cannot be constructed.
Key Takeaways
- IL325298 cannot be analyzed for scope and claims because the authoritative claim text, bibliographic record, and family mapping were not provided in the input.
- A reliable Israel landscape placement for IL325298 requires priority, assignee, family members, claim hierarchy, and status. Those inputs are not present.
FAQs
- Can you summarize the claims of IL325298 without claim text? No. Claim scope in pharmaceuticals depends on the exact claim language and definitions.
- Do you need the publication or grant status to assess landscape impact in Israel? Yes. Remaining term and enforceability depend on status and priority.
- What is the typical approach to an IL drug patent landscape? Map the patent family, extract claim scope, identify remaining term and regulatory overlap, then compare to adjacent MOA patents and likely design-arounds.
- How do dependent claims affect enforcement risk? Dependent claims often narrow coverage, define combinations or dosage specifics, and can create multiple fallback positions.
- What sources usually anchor a landscape for Israel drug patents? Patent publication databases plus the national file record (status, amendments) and cross-family filings.
References
[1] No sources were provided in the prompt.
